Many people with major depressive disorder get no relief from current treatments. Newer combinations of existing medications ...

The most common adverse events in the ketamine groups were headache, cardiorespiratory issues, numbness, tingling, ...

Patients with chronic conditions who are failing on conventional therapies may be suffering from undiagnosed major depression ...

A meta-analysis of 26 trials found that IV ketamine rapidly reduced suicidal and depressive symptoms in patients with major ...

What social risk factors affecting your patients may affect their risk of major depressive disorder more than they realize?

A newer brain stimulation therapy matched ECT for depression while causing less memory loss, offering a potential option for patients concerned about cognitive side effects.

While they share similar depressive and cognitive symptoms, the biological underpinnings of bipolar disorder and major ...

A new meta-analysis of 55 studies involving more than 3 million people has found that 31% of individuals with cannabis use ...

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults, Johnson & Johnson announced. Lumateperone was previously ...

Researchers discover a paradox: high cognitive performance predicts depressive relapse, contradicting traditional expectations.

This week, Mad in America examines three studies related to economic disadvantage and mental health issues. The first finds ...

New findings highlight a critical early window during which mothers may be most vulnerable yet least supported.